Comparative Pharmacology
Head-to-head clinical analysis: CARDIOGRAFIN versus VASCORAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOGRAFIN versus VASCORAY.
CARDIOGRAFIN vs VASCORAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardiografin is an ionic, high-osmolar iodinated contrast agent used for radiographic imaging. It enhances contrast by attenuating X-rays, primarily due to the iodine content. It distributes in the extracellular space and is excreted unchanged by glomerular filtration.
VASCORAY is a fixed combination of iodixanol and calcium sodium edetate. Iodixanol is a nonionic, dimeric, isotonic iodinated contrast medium that increases radiographic contrast by attenuating X-rays. Calcium sodium edetate chelates calcium, potentially reducing contrast-induced nephropathy risk.
Adult: 50-100 mL of CARDIOGRAFIN (diatrizoate meglumine and diatrizoate sodium) 76% intravenously as a bolus or rapid infusion. For cardiac ventriculography, 40-50 mL into the left ventricle. For coronary arteriography, 5-10 mL selective injection per artery.
0.5-1.0 mL/kg intravenously as a single dose, not to exceed 5 mL/kg total.
None Documented
None Documented
Terminal elimination half-life ~2 hours (normal renal function). May be prolonged to >20 hours in severe renal impairment (e.g., CrCl <30 mL/min).
Terminal elimination half-life of 8-12 hours in patients with normal renal function; prolonged in renal impairment.
Primarily renal (glomerular filtration) with >90% of dose excreted unchanged in urine within 24 hours; less than 1% biliary/fecal; negligible metabolism.
Primarily renal (90% unchanged), with 10% biliary/fecal.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent